$IMNM

Immunome Inc.

Immunome is a biotechnology company based in Bothell, Washington, that develops targeted therapies for cancer patients. Its work includes the discovery, design, development and manufacturing of antibody-drug conjugates and other oncology therapeutics. Immunome’s pipeline includes varegacestat, an investigational oral therapy under evaluation for desmoid tumors, and IM-1021, an antibody-drug conjugate in a Phase 1 trial. IM-3050 is a radioligand therapy candidate for solid tumors. Its preclinical solid tumor antibody-drug conjugates include IM-1617, IM-1340 and IM-1335. Immunome also develops linkers and payloads, including HC74, a proprietary inhibitor payload used in its antibody-drug conjugates.

No enriched coverage for $IMNM in the last 7 days.

No SEC Form 4 filings for $IMNM in the last 30 days.

See all $IMNM insider activity →

IMNM sentiment & insider activity

Recent IMNM coverage spans financial news, technology and earnings.

What's driving IMNM

AlphAI scores every news story that mentions IMNM with an AI model for sentiment and relevance, and aggregates insider trades from Immunome Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMNM

Score
$IMNMMedEarnings

Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update

Immunome Inc. (IMNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update November 9, 2026 • Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA) • Initial IM-1021

$IMNMHighAI 9/10

An experimental drug for desmoid tumors cut the risk of progression or death by 84% vs. placebo.

Immunome's varegacestat, an experimental drug for desmoid tumors, reduced risk of progression or death by 84% vs. placebo in a Phase 3 trial. The EMA validated its MAA, a key step for EU approval. The trial met all primary and secondary endpoints, showing significant efficacy and a manageable safety profile. If approved, varegacestat could offer a new treatment option for desmoid tumors.

$IMNMHighAI 8/10

William Blair initiates Immunome stock coverage with outperform rating

William Blair initiated coverage on Immunome Inc. (IMNM) with an Outperform rating and a $35 price target, citing potential 100% upside. The biotech firm is developing varegacestat for desmoid tumors, with projected $1.4B sales by 2032. IMNM stock has fallen 11% in a week. Analysts have a Strong Buy consensus, with targets ranging from $24 to $40. The company recently dosed the first patient in a Phase 1 trial for IM-3050 and secured a licensing deal with Bristol for varegacestat.

Immunome stock holds at Stifel as Bristol deal cleans up license

Stifel maintained a Hold rating and $24.00 price target on Immunome (NASDAQ:IMNM) after its licensing deal with Bristol. The stock trades at $21.17, below the analyst consensus. Immunome paid $20M and issued shares to acquire patent rights, simplifying commercialization. The FDA accepted Immunome's NDA for varegacestat, with a target action date of April 28, 2027. H.C. Wainwright reiterated a Buy rating with a $40 target.

Related tickers